Opposing and hierarchical roles of leukotrienes in local innate immune versus vascular responses in a model of sepsis.
The 5-lipoxygenase (5-LO)-derived leukotrienes (LTs) influence both local innate immunity and vascular responses, but the relative importance of effects on these two processes in sepsis is unknown. In a cecal ligation and puncture model of peritonitis with severe sepsis, 5-LO(-/-) mice showed a reduction in peritoneal neutrophil accumulation and an increase in the number of bacteria in the peritoneal cavity. Despite this impairment of local innate immunity, the null mice exhibited a marked improvement in survival, and this protection was also seen in wild-type animals treated with the LT synthesis inhibitor MK 886. A survival advantage in severe sepsis was also observed in mice treated with the cysteinyl-LT receptor antagonist MK 571, but not with the LTB(4) receptor antagonist CP 105, 696. Protection in the 5-LO(-/-) mice was associated with reduced vascular leak and serum lactate levels. Moreover, wild-type mice treated with MK 571 exhibited less sepsis-induced hypotension. These data demonstrate opposing effects of cysteinyl-LTs on innate immune vs hemodynamic responses, demonstrating protective effects on local immunity and deleterious effects on the vasculature. They also suggest the possible therapeutic utility of targeting vascular events in sepsis with cysteinyl-LT blockade.
Benjamim
Claudia F
CF
Department of Pathology, University of Michigan, Ann Arbor, MI 48109, USA.
Canetti
Claudio
C
Cunha
Fernando Q
FQ
Kunkel
Steven L
SL
Peters-Golden
Marc
M
D000140:Acidosis, Lactic / Q000201:enzymology / Q000235:genetics / Q000517:prevention & control; D000818:Animals; D001094:Arachidonate 5-Lipoxygenase / Q000172:deficiency / Q000235:genetics; D002199:Capillary Permeability / Q000235:genetics / Q000276:immunology*; D002432:Cecum / Q000601:surgery; D003545:Cysteine / Q000378:metabolism / Q000502:physiology; D004195:Disease Models, Animal; D005260:Female; D007022:Hypotension / Q000503:physiopathology / Q000517:prevention & control; D007113:Immunity, Innate / Q000235:genetics; D020024:Leukotriene Antagonists / Q000008:administration & dosage; D015289:Leukotrienes / Q000378:metabolism / Q000502:physiology*; D008026:Ligation; D016859:Lipoxygenase Inhibitors; D008297:Male; D051379:Mice; D018345:Mice, Knockout; D010538:Peritonitis / Q000235:genetics / Q000276:immunology / Q000401:mortality / Q000503:physiopathology; D011422:Propionates / Q000008:administration & dosage; D011677:Punctures; D011804:Quinolines / Q000008:administration & dosage; D018077:Receptors, Leukotriene / Q000378:metabolism; D018102:Receptors, Leukotriene B4 / Q000037:antagonists & inhibitors; D018805:Sepsis / Q000235:genetics / Q000276:immunology* / Q000401:mortality / Q000503:physiopathology*
D020024:Leukotriene Antagonists; D015289:Leukotrienes; D016859:Lipoxygenase Inhibitors; D011422:Propionates; D011804:Quinolines; D018077:Receptors, Leukotriene; D018102:Receptors, Leukotriene B4; C112381:cysteinyl-leukotriene; C059141:verlukast; D001094:Arachidonate 5-Lipoxygenase; D003545:Cysteine